Advanced or Metastatic Breast Cancer clinical trials

Study of SCTB39-1 for advanced solid tumors

This trial tests a new drug called SCTB39-1 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: first finding the right dose, then testing how well it works.

Gene-edited liver transplant to lower rejection risk

This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.

Using a blood test to guide treatment after pancreatic cancer surgery

This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.

Minimally invasive surgery for advanced stomach cancer after chemoimmunotherapy

This trial tests a minimally invasive surgery for stomach cancer that has spread to lymph nodes near the main blood vessels (para-aortic area). The surgery is done after a combination of chemotherapy and immunotherapy to shrink the tumor. It aims to see if this approach is safe and effective.

Post-radiation therapy for head and neck cancer

This trial studies a standard type of radiation therapy given after surgery for head and neck cancer. It aims to see if giving radiation only to certain areas of the neck can control the cancer with fewer side effects.

Study of NTS071 for advanced solid tumors with TP53 Y220C mutation

This trial tests a new drug called NTS071 in people with advanced solid tumors that have a specific mutation in the TP53 gene (called Y220C). The goal is to see if the drug is safe and can help shrink or slow the growth of the tumor.

New immunotherapy for HPV-negative head and neck cancer

This trial tests a new immunotherapy drug called volrustomig for people with advanced head and neck cancer that is not caused by HPV. The goal is to see if giving this treatment based on how the cancer responds can help shrink tumors or stop them from growing.

New drug IBI343 for advanced pancreatic cancer with CLDN18.2 protein

This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Study of AK146D1 injection for advanced solid tumors

This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.

Gastric cancer immunotherapy prediction model

This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.

Study of Navlimetostat for advanced solid tumors with specific gene change

This trial tests a new drug, Navlimetostat (BMS-986504), for people with advanced solid tumors that have a specific genetic change called MTAP deletion or loss. It looks at safety, side effects, and how the drug works in the body.

Comparing a new drug with chemo for pancreatic cancer

This trial tests a new treatment called QLS31905 plus chemotherapy against a placebo plus chemotherapy for people with advanced pancreatic cancer that hasn't been treated yet. It aims to see if the new combination works better.

Tracking ctDNA for Pancreatic Cancer Before Surgery

This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.

Study of HY05350 for mesothelin-positive advanced solid tumors

This clinical trial tests an experimental drug called HY05350 for people with advanced solid tumors that have a specific protein (mesothelin). It aims to see if the drug is safe and effective for cancers that have not responded to standard treatments.

Study of vebreltinib plus furmonertinib for NSCLC with c-Met amplification

This trial tests a combination of two targeted therapies (vebreltinib and furmonertinib) for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a change called c-Met amplification and has stopped responding to earlier EGFR-targeted treatment. It aims to see if adding vebreltinib can help control the cancer.

NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer

MRG006A for advanced solid tumors

This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.

A study of ASP5834 for adults with solid tumors and KRAS mutations

This trial is testing a new drug called ASP5834 for people with advanced solid tumors that have a specific change in the KRAS gene. The study will find the best dose and see if it helps shrink tumors.

Study of HS-10516 combo therapy for advanced kidney cancer

This trial tests a new combination therapy for people with advanced clear cell kidney cancer that has progressed after at least one prior treatment. It aims to see if adding HS-10516 to standard care can help shrink tumors or slow the disease.

New drug combos for advanced lung cancer

This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.

Study of LBL-024 alone or with LBL-007 or toripalimab for advanced melanoma

This trial tests a new drug, LBL-024, either by itself or combined with another drug (LBL-007 or toripalimab) in people with advanced melanoma. The goal is to see if these combinations can shrink tumors or slow cancer growth.

New drug vs chemotherapy for EGFR-mutated lung cancer

This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.

Study of HDM2012 for advanced solid tumors

This trial tests a new drug, HDM2012, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for gastric and colorectal cancers.